Extracorporeal albumin dialysis

Therapeutic Apheresis and Dialysis

Volumn 8, Issue 3, 2004, Pages 217-222

  Abe, Takaya ^a,b   Shono, Mineo ^c   Kodama, Toshihiro ^b   Kita, Yuji ^b   Fukagawa, Masafumi ^a   Akizawa, Tadao ^b  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c Nipro Corporation   (Japan)

Author keywords

Albumin binding toxins; Continuous Albumin Purification System (CAPS); Extracorporeal albumin dialysis (ECAD); Molecular Adsorption in a Recycling System (MARS)

Indexed keywords

ALBUMIN; ALBUMIN BINDING TOXIN; BILIRUBIN; CELLULOSE TRIACETATE; CHARCOAL; RECOMBINANT PROTEIN; TOXIC SUBSTANCE; TOXIN; UNCLASSIFIED DRUG;

ADSORPTION; ARTIFICIAL KIDNEY; ARTIFICIAL LIVER; BIOACCUMULATION; BRAIN FUNCTION; CARDIOVASCULAR FUNCTION; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTINUOUS ALBUMIN PURIFICATION SYSTEM; CONTROLLED STUDY; DEVICE; DIALYSATE; DIALYSIS MEMBRANE; EVALUATION; EXTRACORPOREAL ALBUMIN DIALYSIS; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MOLECULAR ADSORPTION RECYCLING SYSTEM; MOLECULAR SIZE; POROSITY; PRIORITY JOURNAL; SURVIVAL RATE; TECHNIQUE;

ALBUMINS; BILIRUBIN; HEMOFILTRATION; HUMANS; PROTEIN BINDING; RENAL DIALYSIS;

EID: 3142544176     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-0968.2004.00148.x     Document Type: Conference Paper

References (21)

1. Niwa T, Aiuchi T, Emoto Y, Miyazaki T, Maeda K. Albumin-bound, non-dialyzable furancarboxylic acid accumulated in uremic serum is an inhibitor of mitochondrial respiration. Artif Organs 1991;15:290.
2. Bowmer CJ, Lindup WE. Decreased drug binding in uraemia. Effect of indoxyl sulphate and other endogenous substances on the binding of drugs and dyes to human albumin. Biochem Pharmacol 1982;31:319-23.
3. Ferenci P, Schafer DF, Kleinberger G, Hoofnagle JH, Jones EA. Serum levels of gamma-aminobutyric-acid-like activity in acute and chronic hepatocellular disease. Lancet 1983;2:811-4.
4. Trewby PN, Warren R, Contini S et al. Incidence and pathophysiology of pulmonary edema in fulminant hepatic failure. Gastroenterology 1978;74:859-65.
5. Kragh-Hansen U. Structure and ligand binding properties of human serum albumin. Dan Med Bull 1990;37:57-84.
6. Kita Y, Kodama T, Ageta S, Abe T. In vitro study of bilirubin elimination by dialysis. J Jpn Soc Dial Ther 1994;27:623.
7. Kita Y, Ageta S, Kodama T, Abe T. In vitro study of bilirubin elimination by dialysis. J Jpn Soc Dial Ther 1995;28:957-64.
8. Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins. ASAIO J 1993;39:M621-5.
9. Heemann U, Treichel U, Loock J et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002;36:949-58.
10. Stange J, Mitzner SR, Risler T et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999;23:319-30.
11. Kodama T, Ageta S, Kita Y et al. Experimental investigation of a continuous albumin purification system. J Jpn Soc Dial Ther 1997;30:845.
12. Mitzner S, Williams R. Albumin dialysis MARS 2003: what evidence, how to proceed?. Liver Int 2003;23:3-4.
13. Mitzner SR, Stange J, Klammt S, Peszynski P, Schmidt R, Noldge-Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001;12:S75-82.
14. Awad SS, Sawada S, Soldes OS et al. Can the clearance of tumor necrosis factor alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system?. ASAIO J 1999;45:47-9.
15. Guo LM, Liu JY, Xu DZ et al. Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int 2003;23:16-20.
16. Zeh N, Rossi SS, Hofmann AF et al. The effect of extracorporeal albumin dialysis on plasma phospholipid fatty acids in patients with end-stage liver disease. Liver Int 2003;23:34-8.
17. Loock J, Peters E, Stange J et al. Change of human serum albumin amino acid patterns (Fischer-index) during a new dialysis treatment for liver failure (MARS). Int J Artif Organs 1997;20:500.
18. Mitzner SR, Stange J, Klammt S et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS. results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-86.
19. Catalina MV, Barrio J, Anaya F et al. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int 2003;23:39-43.
20. Lepore MJ, Mckenna PJ, Martinez DB, Stutman LJ, Bonanno CA, Conklin EF. Fulminant Hepatitis with Coma Successfully Treated by Plasmapheresis and Hyperimmune Australia-Antibody-Rich Plasma. Am J Gastroenterol 1972;58:381-9.
21. Abe T, Hasegawa H, Yamashita M et al. Plasma exchange (PE) in hepatic failure (HF): PE alone is unsafe and should be associated with HD in series. Ther Apher Dial 2003;7:A5.